What changed for Cardiomyopathy
A plain English summary of what recently moved in the public data Voxsanity tracks for Cardiomyopathy. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 295 to 301 (+6)
- Trials on record 1,494 to 1,507 (+13)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Cardiomyopathy in July 2026. Voxsanity tracks 2 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 57 trials tracked for Cardiomyopathy that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05556343 · results posted 2 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05556343) tested an investigational medicine called MYK-224. A total of 18 people took part in Part A (the initial dosing phase), of whom 17 completed that phase. Sixteen participants then moved into Part B, an open-label extension (meaning everyone knew what medicine they were receiving), though none had completed Part B at the time the results were submitted. The trial was primarily measuring a range of safety-related outcomes — specifically, unwanted medical events, irregular heart rhythms, and changes in basic body mea...
-
NCT04023227 · results posted 11 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04023227) enrolled 922 people in total — 462 in the sacubitril/valsartan group and 460 in the enalapril group. The trial compared these two heart-related medicines in people with heart failure. It was measuring three things together as its main goal: how long it took before a participant died from a heart-related cause, how long it took before a participant was first admitted to hospital due to heart failure, and how much a particular blood marker (called NT-proBNP, a substance that rises when the heart is under stress) ch...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05492500 · results posted 18 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05492500) enrolled people with heart failure to test a medicine called ponsegromab. The main part of the trial (Cohort A) was a blinded comparison — meaning neither participants nor researchers knew who was getting which treatment — and included 433 people split across a placebo (dummy treatment) group and three different doses of ponsegromab: 100 mg, 200 mg, and 300 mg. A smaller, open-label group (Cohort B, where everyone knew what they were receiving) included 22 people across the same three doses. The trial's main focu...
-
NCT04219826 · results posted 24 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04219826) looked at a drug called aficamten (also referred to as CK-3773274) in people with a heart condition called hypertrophic cardiomyopathy (HCM) — a condition where the heart muscle becomes abnormally thick. A total of 96 people took part across six groups: some had a type where blood flow out of the heart is partially blocked (obstructive HCM, or oHCM), and others had a type without that blockage (non-obstructive HCM, or nHCM). Some participants received aficamten, some received a placebo (a dummy treatment), and on...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06269640 · results posted 18 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled just one participant who underwent a procedure called SESAME (SEptal Scoring Along Midline Endocardium). This is a technique that involves entering the heart muscle wall between the two lower chambers (the septum), navigating through it, and making a cut along it. The trial was primarily looking at whether the procedure could be completed successfully, and whether any serious safety events occurred during the hospital stay. The reported data shows that the one participant was recorded as having met the definition of...
-
NCT04153149 · results posted 21 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04153149) enrolled 655 participants in its main double-blind phase — 329 received a placebo (an inactive treatment) and 326 received vutrisiran. The trial was measuring outcomes in people with a heart condition related to a protein build-up disorder called transthyretin amyloid cardiomyopathy. The main thing the trial was tracking was a combined count of deaths from any cause and serious heart-related events (such as hospital admissions for heart problems or urgent heart failure visits). A separate, smaller group of partic...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00335036 · results posted 17 July 2025
According to the results reported on ClinicalTrials.gov, this trial involved 748 people in total — 525 in a group using "thin leads" and 223 in a group using "Gore PTFE-coated leads." (These are types of wires used with implantable heart devices called ICDs.) The trial was measuring how well each type of lead continued to function over time, how easy they were to remove when needed, and tracking certain events that occurred along the way. All participants who started the trial were recorded as completing it. The reported data shows that when looking at lead survival to five years (meaning the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04766892 · results posted 20 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04766892) enrolled 30 people who all received mavacamten. All 30 were included in the safety and analysis populations, while 24 completed the study and 6 did not finish. The trial was primarily focused on tracking various types of medical events — called adverse events — that occurred while participants were taking the study drug. An adverse event simply means any unwanted medical occurrence that happens during a study, whether or not it is thought to be related to the treatment. The reported data shows that out of the 30...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02791230 · results posted 3 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02791230) involved three groups of participants. One group (Cohort A) included 170 people who had received the study medicine, tafamidis, throughout both an earlier study and this extension study, and 82 people who had received a placebo (inactive treatment) in the earlier study before switching to tafamidis in this extension. A much larger second group (Cohort B) included 1,481 people who only joined during this extension study and received tafamidis. The trial was measuring, among other things, how long participants surv...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03366649 · results posted 16 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03366649) enrolled 34 participants in the main treatment group (called "UMA – Group 1"), of whom 26 completed the study. A second treatment group and a retrospective comparison group were listed but had zero participants recorded, so all reported results relate only to the 34-person group. The trial was measuring changes in the severity of a heart valve condition called functional mitral regurgitation — where the mitral valve leaks blood back in the wrong direction — as well as a range of other things including survival, s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00628745 · results posted 22 November 2024
According to the results reported on ClinicalTrials.gov, this was a large registry-style study involving 6,718 people in total across five groups. The groups were defined by the dose of tafamidis they received — either 20 mg, 61/80 mg, a switch from 20 mg to 61/80 mg, or another dose — as well as a group of people who did not receive tafamidis. The study was primarily tracking unwanted medical events (called adverse events) that occurred during treatment, as well as deaths from any cause. It also collected information at the start of the study on how well participants could move around and car...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03719040 · results posted 19 August 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 870 people into the Physiologic Pacing Registry. The study was looking at a type of pacemaker lead (the wire that delivers electrical signals to the heart) designed to pace the heart in a more "physiologic" — that is, more naturally timed — way. Of the 870 who joined, 849 went through an attempted lead implant procedure, and 667 people completed the full six-month follow-up period. The reported data shows that of the 849 people who had an implant attempted, 768 were recorded by their treating doctor as having had a s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04561778 · results posted 7 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04561778) enrolled 100 people in total — 50 in each group. One group received a heart pacing approach called HOT-CRT, and the other received a more established pacing approach called biventricular (BiV) pacing. Both are types of cardiac resynchronisation therapy, which use a small implanted device to help the heart's chambers beat in a more coordinated way. The trial was measuring changes in heart pumping function over six months, as well as tracking serious complications and other health events. The reported data shows t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04424914 · results posted 19 July 2024
According to the results reported on ClinicalTrials.gov, this study (NCT04424914) enrolled a total of 347 people across three groups: 56 people who were diagnosed with a specific type of heart condition called ATTR-CM (a disease where a protein called transthyretin builds up in the heart), 259 people who did not have ATTR-CM, and 32 people whose results could not be fully evaluated. All participants had a form of heart failure known as "heart failure with preserved ejection fraction" (HFpEF), meaning their heart pumps normally but is too stiff — and the trial was designed to measure how common...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03842163 · results posted 12 February 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 812 participants in total, though the main analysis included 766 people who completed the study. The trial was looking at people who had an unexplained thickening of the heart's main pumping chamber (called left ventricular hypertrophy, or LVH) and aimed to measure how often a specific type of protein build-up in the heart — known as amyloidosis — might be behind that thickening. To do this, researchers used a special nuclear imaging scan of the heart, as well as blood and genetic tests. The reported data shows that,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03997383 · results posted 18 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03997383) involved 360 people in total — 179 received a placebo and 181 received patisiran during the initial blinded phase, where neither participants nor researchers knew who was getting which treatment. After that phase, participants moved into an open-label extension where everyone received patisiran. The trial was measuring things like how far participants could walk in six minutes, how they felt about their heart condition using a questionnaire, and whether there were differences in deaths, hospital visits, or urgent...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00701220 · results posted 18 July 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 9 people in total — 3 with ischemic cardiomyopathy (a type of heart weakness caused by reduced blood supply) and 6 with non-ischemic cardiomyopathy (heart weakness from other causes). Of those, 5 people completed the study (1 from the ischemic group and 4 from the non-ischemic group), while 4 did not complete it. The trial was measuring changes in certain cells in the blood called endothelial progenitor cells (EPCs) — early-stage cells that circulate in the bloodstream — using a laboratory test called the Aldefluor as...
-
NCT03103490 · results posted 7 April 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 28 participants, all of whom completed the study with no drop-outs. The trial was looking at a radioactive imaging agent called 18F-FSPG, used with specialised body scanners (PET/MRI or PET/CT), to see whether it could pick up signs of sarcoidosis — an inflammatory condition — in the heart and elsewhere in the body. The reported data shows that when the scan images were reviewed for signs of sarcoidosis in the heart, 2 out of the 28 participants showed patterns of 18F-FSPG uptake (meaning the imaging agent was absorb...
-
NCT03458130 · results posted 16 November 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03458130) enrolled 49 people in total, split across three groups: 16 people received a lower dose of AG10 (400 mg), 16 received a higher dose of AG10 (800 mg), and 17 received a placebo (a dummy treatment with no active ingredient). All 49 participants completed the trial. The study was measuring changes in basic body signs — blood pressure (both the "top" and "bottom" numbers), heart rate, breathing rate, and body temperature — over 28 days. It also looked at a laboratory measure of how stable a protein called TTR remaine...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03442764 · results posted 9 August 2022
According to the results reported on ClinicalTrials.gov, this trial involved 59 people split across three groups — Group 1 (19 people), Group 2 (21 people), and a placebo group (19 people). The trial was primarily measuring how often participants in each group experienced unwanted health events (called adverse events) after starting the study treatment. Nearly all participants finished the trial; only one person in Group 1 did not complete it. The reported data shows that when looking at participants who experienced at least one unwanted health event during the study, 88.9% of Group 1, 90.5%...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04066738 · results posted 18 May 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 2 participants, all of whom had scarring of the heart muscle (known as myocardial scar). Both participants completed the study. The trial was looking at how a pacing technique called "multipoint pacing" (MPP) — where a pacemaker-like device stimulates the heart from more than one spot at a time — affected the pumping function of the heart. Specifically, it measured changes in how forcefully and quickly the heart's main pumping chamber (the left ventricle) could build up pressure, compared to the heart's own natural rh...
-
NCT02351856 · results posted 31 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02351856) enrolled 8 participants, all of whom received the study drug ARRY-371797. None of the 8 participants completed the study — all 8 left before it finished, though the reasons for this are not detailed in the reported data. The trial was focused on monitoring and recording a range of health measurements in participants while they were taking the study drug, including any unwanted medical events (called adverse events), blood test results, physical examination findings, vital signs (such as blood pressure and heart r...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03022461 · results posted 2 December 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 25 people, all of whom were already taking part in an ongoing study of the HM3 heart pump device (a mechanical device implanted to help a failing heart pump blood). Of the 25 who started, 22 completed the study and 3 did not. The trial was measuring how many participants survived over time, as well as tracking their quality of life, physical function, heart-failure symptoms, adverse (unwanted) events, and whether the device had any malfunctions. The reported data shows that 61% of participants survived over the study...
-
NCT03470545 · results posted 4 October 2021
According to the results reported on ClinicalTrials.gov, this trial (known as EXPLORER-HCM) enrolled 251 adults with a heart condition called hypertrophic cardiomyopathy — 123 people received the investigational drug mavacamten and 128 received a placebo (a dummy treatment with no active ingredient). The trial ran for 30 weeks and was primarily measuring whether participants achieved a meaningful improvement in exercise capacity (how well the heart and lungs work during exercise) and/or their functional symptom class, a doctor-rated score of how much a heart condition limits daily activity. T...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02568072 · results posted 5 August 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02568072) enrolled 120 participants in a single study group, of whom 68 completed the study and 52 did not. The trial was measuring changes in heart muscle structure — specifically, the thickness and complexity of different layers of the heart wall — before and after a period of around seven months. These measurements were taken using two types of heart imaging: ultrasound (echocardiography) and a cardiac MRI scan (cardiac magnetic resonance imaging). The reported data shows the following numbers for the heart muscle meas...
-
NCT00935012 · results posted 5 January 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT00935012) enrolled 31 people, all of whom received tafamidis 20 mg. The trial was looking at a heart condition and tracked participants over up to 60 months (five years). It measured how participants felt overall compared to their last visit (using a self-reported scale called the Patient Global Assessment), how much their heart-related physical limitations changed over time (using a standard four-level scale called the NYHA classification), and how far they could walk in six minutes. Notably, only 2 of the 31 participants...
-
NCT02509156 · results posted 5 November 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02509156) looked at a treatment called Allo-MSCs (donor-derived stem cells) compared to a placebo (an inactive substance) in people with heart failure. The trial had two stages: an open-label lead-in phase, where 6 people received the stem cell treatment with no placebo comparison, and a randomised phase, where participants were randomly assigned to either the stem cell group (14 people) or the placebo group (17 people). In the randomised phase, 12 of the 14 in the stem cell group and 16 of the 17 in the placebo group comp...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02892448 · results posted 24 August 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 35 people across three groups: 12 who had a single (unilateral) metal-on-metal hip resurfacing implant, 12 who had both hips resurfaced with metal-on-metal implants, and 11 who had a non-metal-on-metal total hip replacement. The trial was measuring heart function using a specialised type of MRI scan, to see whether metal hip implants — which can release tiny amounts of metal particles into the body — were associated with any differences in how the heart looks and works compared to non-metal implants. Of the 35 who sta...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00883415 · results posted 21 May 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT00883415) enrolled 20 participants in a single group, with 18 completing the study and 2 not completing it. There was no comparison group — all participants received the same intervention, and measurements were taken before treatment began and again six months after starting anaemia (low red blood cell) therapy. The main thing the trial was looking at was whether the heart's uptake of glucose (sugar used for energy) changed over that period, measured using a special imaging scan called a PET scan. The reported data shows...
-
NCT02164721 · results posted 4 March 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 participants, all of whom received a type of heart device called a CRT-D (a combined cardiac resynchronisation therapy and defibrillator device). All 30 participants completed the study. The trial was measuring changes in heart function over six months, focusing mainly on how well the heart's main pumping chamber was working — measured by a figure called the left ventricular ejection fraction (LVEF), which is a percentage that indicates how much blood the heart pumps out with each beat. The reported data shows tha...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 57 reported results for Cardiomyopathy
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, cardiomyopathy receives a very large amount of public research funding from the United States government, and that investment has been rising year on year. This is an encouraging signal for patients, suggesting that researchers and funding bodies regard cardiomyopathy as a serious priority worthy of sustained scientific attention. Growing investment at this scale gen...
See the full Cardiomyopathy page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.